Claims
- 1. An isolated polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO: 120-197, 275-348, 373-398, 406-409, 413-415, 417, 456-463, 465, 488-509, 512, 513 and 624-725.
- 2. An isolated polypeptide comprising a sequence selected from the group consisting of:
(a) sequences having at least 75% identity to a sequence provided in SEQ ID NO: 120-197, 275-348, 373-398, 406-409, 413-415, 417, 456-463, 465, 488-509, 512, 513 and 624-725; (b) sequences having at least 90% identity to a sequence provided in SEQ ID NO: 120-197, 275-348, 373-398, 406-409, 413-415, 417, 456-463, 465, 488-509, 512, 513 and 624-725; and (c) sequences having at least 95% identity to a sequence provided in SEQ ID NO: 120-197, 275-348, 373-398, 406-409, 413-415, 417, 456-463, 465, 488-509, 512, 513 and 624-725, wherein the polypeptide possesses at least one functional property that is substantially the same as a functional property of a sequence of SEQ ID NO: 120-197, 275-348, 373-398, 406-409, 413-415, 417, 456-463, 465, 488-509, 512, 513 and 624-725.
- 3. An isolated polynucleotide that encodes a polypeptide according to any one of claims 1 and 2.
- 4. An isolated polynucleotide of claim 3, wherein the polynucleotide comprises a sequence selected from the group consisting of: sequences provided in SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623.
- 5. An isolated polynucleotide comprising a sequence selected from the group consisting of:
(a) complements of a sequence provided in SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623; (b) reverse complements of a sequence provided in SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623; (c) reverse sequences of a sequence provided in SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623; and (f) sequences having at least 95% identity to a sequence of SEQ ID NO: 1-119, 198-276, 349-372, 399-405, 410-412, 416, 418-455, 464, 466-487, 510, 511 and 514-623.
- 6. An isolated polynucleotide comprising a sequence selected from the group consisting of:
(a) sequences that are a 200-mer of an isolated polynucleotide according to any one of claims 3, 4 and 5; (b) sequences that are a 100-mer of an isolated polynucleotide according to any one of claims 3, 4 and 5; and (c) sequences that are a 40-mer of an isolated polynucleotide according to any one of claims 3, 4 and 5.
- 7. An expression vector comprising an isolated polynucleotide according to any one of claims 3-6.
- 8. A host cell transformed with an expression vector according to claim 7.
- 9. An isolated polypeptide comprising at least a functional portion of an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO: 120-197, 275-348, 373-398, 406-409, 413-415, 417, 456-463, 465, 488-509, 512, 513 and 624-725.
- 10. A fusion protein comprising at least one polypeptide according to any one of claims 1, 2 and 9.
- 11. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of any one of claims 1 and 2.
- 12. A composition comprising an isolated polypeptide according to any one of claims 1, 2 and 9, and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 13. A composition comprising an isolated polynucleotide according to any one of claims 3-6 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 14. A composition comprising a fusion protein according to claim 10 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 15. A method for treating a disorder in a patient, comprising administering to the patient a composition comprising of any one of claims 12-14.
- 16. The method of claim 15, wherein the disorder is selected from the group consisting of: inflammatory disorders; cancer; and neurological disorders.
- 17. A method for stimulating keratinocyte growth and motility in a patient, comprising administering to the patient a composition of any one of claims 12-14.
- 18. A method for inhibiting the growth of cancer cells in a patient, comprising administering to the patient a composition of any one of claims 12-14.
- 19. A method for modulating angiogenesis in a patient, comprising administering to the patient a composition of any one of claims 12-14.
- 20. A method for inhibiting angiogenesis and vascularization of tumors in a patient, comprising administering to a patient a composition of any one of claims 12-14.
- 21. A method for modulating skin inflammation in a patient, comprising administering to the patient a composition of any one of claims 12-14.
- 22. A method for stimulating the growth of epithelial cells in a patient, comprising administering to the patient a composition of any one of claims 12-14.
- 23. A method for inhibiting the binding of HIV-1 to leukocytes in a patient, comprising administering to the patient a composition of any one of claims 12-14.
- 24. A method for treating a disorder, comprising reducing the amount or activity of a polypeptide of any one of claims 1, 2 and 9.
- 25. The method of claim 24, comprising administering an antibody of claim 11.
- 26. The method of claim 24, comprising administering an anti-sense oligonucleotide that binds specifically to a polynucleotide of any one of claims 3-6.
- 27. The method of claim 24, comprising administering a small interfering RNA molecule that corresponds to a polynucleotide of any one of claims 3-6.
- 28. The method of claim 24, wherein the disorder is characterized by tumor growth, aberrant epithelial cell growth or aberrant smooth muscle growth.
- 29. The method of claim 24, wherein the disorder is selected from the group consisting of: atherosclerosis, cardiovascular disease, leiomyosarcoma, fibroids, psoriasis, Crohns disease and epithelial cancers.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/NZ99/00051 |
Apr 1999 |
WO |
|
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/866,050, filed May 24, 2001, which is a continuation-in-part of U.S. application Ser. No. 09/312,283, filed May 14, 1999, which is a continuation-in-part of U.S. application Ser. No. 09/188,930, filed Nov. 9, 1998, now U.S. Pat. No. 6,150,502, which is a continuation-in-part of U.S. application Ser. No. 09/069,726, filed Apr. 29, 1998, now abandoned, and claims priority to International Patent Application No. PCT/NZ99/00051, filed Apr. 29, 1999, U.S. Provisional Application No. 60/206,650, filed May 24, 2000, and U.S. Provisional Application No. 60/221,232, filed Jul. 25, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60206650 |
May 2000 |
US |
|
60221232 |
Jul 2000 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09866050 |
May 2001 |
US |
Child |
10152661 |
May 2002 |
US |
Parent |
09312283 |
May 1999 |
US |
Child |
09866050 |
May 2001 |
US |
Parent |
09188930 |
Nov 1998 |
US |
Child |
09312283 |
May 1999 |
US |
Parent |
09069726 |
Apr 1998 |
US |
Child |
09188930 |
Nov 1998 |
US |